An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

• Status: Completed
• Trial end date: 2019-09-27
• Target enrollment: 0
• Participant gender: All

Summary

This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator

• Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol

• Able to comply with this extension study protocol (MO25757)

Exclusion Criteria:

• Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study

• Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation

• A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial

• Evidence of any other disease that would put the participant at high risk for treatment-related complications